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Abstract
Background: One of the most important measures for ascertaining the impact of tobacco on a
population is the estimation of the mortality attributable to its use. To measure this, a number of
indirect methods of quantification are available, yet there is no consensus as to which furnishes the
best information. This study sought to provide a critical overview of the different methods of
attribution of mortality due to tobacco consumption.
Method: A search was made in the Medline database until March 2005 in order to obtain papers
that addressed the methodology employed for attributing mortality to tobacco use.
Results: Of the total of 7 methods obtained, the most widely used were the prevalence methods,
followed by the approach proposed by Peto et al, with the remainder being used in a minority of
studies.
Conclusion: Different methodologies are used to estimate tobacco attributable mortality, but
their methodological foundations are quite similar in all. Mainly, they are based on the calculation
of proportional attributable fractions. All methods show limitations of one type or another,
sometimes common to all methods and sometimes specific.
Background
Since the association between tobacco and mortality was
first discovered [1,2], the task of attributing a given
number deaths to smoking has been and continues to be
a controversial process, beset by limitations and ques-
tioned from different quarters, including the powerful
tobacco industry. With the appearance of the successive
revisions of the International Classification of Diseases
(ICD), there has been considerable progress in the process
of categorizing mortality, but little in methods for attrib-
uting mortality to risk factors such as tobacco. Obtaining
reliable estimates of the impact of tobacco on mortality
would facilitate to have a clearer picture of the problem
caused by smoking and would be of help in the planning
of health policy.
The task of quantifying smoking-attributable mortality
has been performed mainly through indirect methods.
This review sought to list and to describe the different
methods of estimating mortality attributed to tobacco
use, to indicate the principal methodological differences
existing among them, and to identify the possible sources
of variability in the results.
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Methods
In order to obtain papers that addressed the methodology
employed for attributing mortality to tobacco use, a
search was made in the Medline database until March
2005, using the terms, mortality,  attribut,*method* and
tobacco or smok*. The search was completed with a manual
review of the bibliographic references cited by the papers
retrieved and of other publications, such as the mono-
graphs published by the Centers for Disease Control and
Prevention (CDC). The main inclusion criteria was the
use of an epidemiological method to estimate attributable
mortality. Papers describing mortality, such as cohort fol-
low-up or mortality studies were excluded unless an epi-
demiological analysis had been used. Animal studies and
communications presented at congresses were also
excluded from the search.
The estimation of attributable mortality is also applied to
other risk factors in addition to tobacco, such as alcohol
consumption or obesity. In order to avoid the exclusion of
valid methodologies the search was repeated without
restricting it to tobacco or smoke.
Results
The search yielded a total of 372 papers. Of these, 74 were
finally included, as the rest did not apply mortality attri-
bution methods. Some papers included more than one
method. The unrestricted search, without the terms
tobacco or smoke, did not furnish any new alternative
methodology.
Revision of the 74 papers enabled us to identified 2 types
of mortality attribution procedures for the specific case of
tobacco. The first one is based on individual analysis of
deaths to ascertain if tobacco use had any role in mortal-
ity. Only three studies applied this procedure [3-5]. The
second is based on the application of indirect methods
and constitutes the most commonly used methodology
for attributing mortality. The total number of papers that
employed this indirect methodology was 73, with 61 of
these being yielded by the automatic and 12 by the man-
ual search.
Seven indirect methods for estimating tobacco-attributa-
ble mortality were identified. The applied methodology in
these 7 methods can be classified under four categories:
Prevalence-based analysis (Prevalence-based analysis in
cohort studies, prevalence-based analysis in case-control
studies and the basic method), Peto and colleagues'
method, methodologies based on the calculation of
excess mortality (Garfinkel's and Roger's method) and
predictive models (Prevent). The methods differ in terms
of calculation processes, information requirement, data
sources and assumptions required for their application. A
summary of these methods is showed in Table 1. The
main characteristics of the different indirect methods are
described below.
a) Prevalence-based analysis
Prevalence-based analysis or prevalence-risks models are
based on the different distributions of the risk of dying
from various tobacco-related diseases in relation to the
prevalence of tobacco consumption in the population.
To apply these methods it is necessary to know the preva-
lence of smoking in the study population, the total
number of deaths due to diseases causally related to
tobacco use, and a measure that summarizes the increased
risk of dying due to these causes among smokers and ex-
smokers.
We can distinguish 3 methods due mainly to data source:
- Prevalence-based analysis in cohort studies
This method is the most widely employed in the literature
[4,6-51].
Attributable deaths are calculated for each cause of mor-
tality using the following formula:
AM = OM * PAF;
where AM is the mortality attributed to tobacco, OM the
observed mortality, and PAF the population attributable
fraction.
To calculate PAF, different methods exist [52,53], though
the most widely used is based on the formula proposed by
Levin [54] which divides the population into various cat-
egories according to tobacco use (non-smokers, ex-smok-
ers and smokers):
PAF = ((p0 + p1RR1 + p2RR2)-1)/(p0 + p1RR1 + p2RR2);
where p0, p1 and p2 represent the prevalence of non-smok-
ers, smokers and ex-smokers, respectively. RR1 and RR2
refer to the risk of dying for any cause of smokers and ex-
smokers respectively compared to a baseline population
of non-smokers.
Data are drawn from registries in the case of observed
mortality and from surveys in the case of smoking preva-
lence. The relative risks (RRs) employed in the calcula-
tions are extracted mainly from the prospective cohort
study conducted by the American Cancer Society, i.e., the
Cancer Prevention Study II (CPS II) with follow-up at 4
[55] and 6 [56] years.
A modification of this method was proposed in the 1992
Surgeon General's report "Smoking and Health in theB
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Table 1: Methods used to estimate tobacco attributable mortality
Method Data employed Data source Method applied to estimate 
mortality due to:
Weaknesses Strengths Estimations calculated
Prevalence-based 
analysis in cohort 
studyes/SAMMEC (n = 
52)
Prevalence National Statistics Tobacco consumption, 
exposure to environmental 
tobacco smoke (ETS), 
obesity, alcohol intake,...
- Does not take latency into 
account.
- Worldwide use. Attributable mortality 
for all causes.
Relative Risks: Smokers, non-
smokers and former smokers
Cohort study - Application of risks other 
than CPS.
Method proposed by 
Peto and colleagues (n 
= 6)
Relative Risks: Smokers and 
non-smokers
CPS II Tobacco consumption. - Assumes constant worldwide 
lung cancer mortality rates among 
never smokers.
- Worldwide use. Attributable mortality 
for all causes.
Lung cancer death rates: Global 
(non smokers + smokers + 
former smokers), non-smokers 
and smokers.
National Statistics/CPS II - Assumes the same latency for all 
death causes related to tobacco.
- Mortality estimation in 
absence of smoking 
prevalence.
- Does not take into account 
former smokers.
- Takes latency into account 
for lung cancer.
Basic method (n = 1) Lung cancer death rates National Statistics Tobacco consumption. - Partial view of attributable 
mortality (only used to estimate 
mortality by lung cancer).
- Takes into account induction 
time.
Lung cancer death rate 
attributable and not 
attributable to active 
smoking.
Prevalence National statistics/
Estimated
- Use of constants. - Estimates smoking-adjusted 
RR in different time periods.
Lung cancer relative risk Calculated - High need of information.
Packs of cigarettes smoked National statistics/
Estimated
- Rate ratios for former smokers.
Age of starting/giving up 
tobacco consumption
National statistics/
Estimated
- Assumes constant worldwide 
lung cancer mortality rates among 
never smokers.
Constants Previous studies
Prevent method (n = 
2)
Composition of the population National Statistics Tobacco consumption and 
general scenarios of 
effective health promotion.
- High need of information. -Takes into account the 
multiplicity of cause or effect.
Attributable mortality 
for all causes.
Mortality (population) and birth 
(women) rates
National Statistics - Proportional decrease in risk 
reduction related to time.
Latency and delay Previous studies - To measure the results of 
intervention policies.
Time-Tendency of tobacco 
consumption.
Personal interviews
Relative risks CPS II
Prevalence-based 
analysis in case-control 
studyes (n = 4)
Mortality observed National Statistics Tobacco consumption and 
exposure to ETS.
- Case-control study design. - Specific risk dates. Attributable mortality 
for all causes.
Exposure prevalence: case or 
controls
Case-control study - Recall bias.
Odds Ratios Case-control study
Garfinkel's method 
(n = 2)
Mortality observed National Statistics Tobacco consumption and 
alcohol intake.
- Partial view of the attributable 
mortality (only used to estimate 
cancer mortality).
- Necessary dates are few. Cancer deaths 
attributable to smoking.
Cancer mortality rates in non 
smokers.
American Cancer Society - Assumes constant worldwide 
cancer mortality rates among 
never smokers.
- Does not use risks or 
prevalence.
Rogers' method (n = 1) Mortality observed (all causes) National Statistics Tobacco consumption. - Availability of mortality 
registries.
- Risks calculated ad hoc. Attributable mortality 
for all causes.
Prevalence (7 categories) Surveys - Has a population representative 
survey about health-risks.
- The population division is 
more reliable.
Odds Ratios Discrete-time hazard 
models
- Assumption: smoking status 
remains steady since the survey 
about health-risks.BMC Public Health 2008, 8:22 http://www.biomedcentral.com/1471-2458/8/22
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Americas" [57]. The authors created an index for measur-
ing the smoking maturity in a population, based on a
comparison of lung cancer rates. This index is multiplied
by the disease-specific PAF to obtain an adjusted disease-
specific PAF for a country.
The CDC's SAMMEC (Smoking-Attributable Mortality,
Morbidity, and Economic Cost) computer software appli-
cation [58] uses this methodology. SAMMEC is a software
package commonly used in the United States to estimate
attributable mortality due to smoking, years of potential
life lost and indirect mortality costs. SAMMEC computes
PAF automatically after the user includes prevalence of
tobacco consumption. Furthermore, the user must supply
the number of deaths by 5-years age groups from 35 or
older, for each smoking-related diagnosis. Estimations
from SAMMEC can include attributed deaths to fires and
secondhand smoke. The Simsmoke model, a model that
predicts the effect of policies on smoking rates and deaths
attributable to smoking, uses this computer application to
estimate deaths attributable to smoking.
Apart from being employed for calculating mortality due
to tobacco use, this method has also been used for esti-
mating mortality associated with exposure to environ-
mental tobacco smoke [59-61], alcohol intake
[8,18,21,24,29,62-65], illicit drugs [18,21], obesity
[66,67], oral contraceptive use [68], hypertension status
[69], cardiovascular processes [70], and diabetes status
[71].
Prevalence-based analysis in case-control studies
Employing a similar calculation procedure to the previous
method, this one emerged as a consequence of the objec-
tions raised by certain researchers about using RRs to esti-
mate smoking attributable mortality from other countries
[72]. This method has been used to estimate mortality
attributable to tobacco use [73-75] in China when the epi-
demic was still in the initial phase.
To apply this method, it is necessary to know the total
deaths for all causes among subjects aged 35 years or more
for a given period of time. By interviewing survivors,
information is collected retrospectively on smoking hab-
its of deceased subjects 15 years before their death. Based
on a case-control study risks are estimated.
Once these risks obtained, the population attributable
fraction (PAF) can then be calculated, applying the for-
mula:
PAF = P*(1-(1/RR));
where P is the proportion of deaths occurring among
smokers and RR the relative risk calculated as OR after
completion of a case-control study.
When the PAF has been calculated, deaths attributed to
tobacco use (AM) in the study population can be esti-
mated as follows:
AM = OM*PAF
Basic model
The Basic model [76] was originally applied in the setting
of occupational cohort studies, to assess confounding
generated by tobacco use.
This model has been employed in only one study [76] to
estimate non-tobacco-attributable lung cancer mortality
rates. Unlike the previous methods, different processes are
specified here for calculating the RRs of lung cancer in
smokers and ex-smokers versus non-smokers. From a
paper previously published [77] authors adapted two
functions to compute rate ratios. Both of them take into
account duration and intensity of smoking.
Lung cancer rate not attributable to smoking (Io) can be
calculated as follows:
; where I is the overall lung cancer
mortality rate.
b) Method proposed by Peto et al
Although this method could be defined as a prevalence-
risk model, particularities in its calculation procedure and
assumptions would classify it separately.
Peto et al. [78,79] established a method for estimating
tobacco-related mortality in which the need for data, espe-
cially for lung cancer estimates, is less demanding than in
any of the other procedures reviewed. These authors pos-
tulate that lung cancer mortality is an indicator of the
maturity of the smoking epidemic in a population, and
thus, that tobacco-attributable mortality can be estimated
by lung cancer mortality. This model may estimate mor-
tality independently of the prevalence of smoking in the
study population.
To apply this method, one needs to know the age- and sex-
specific lung cancer mortality rates in the target country
(CLC) and also in never-smokers of the same population
(NLC), the relative risks for all diseases and disorders caus-
ally related to tobacco, except lung cancer; and the cause-
specific lung cancer mortality rates in smokers (S*LC) and
never-smokers (N*LC), taken from a cohort study. Peto et
al used data drawn from the CPS II.
Io
I
PP R RP R R = ++ 01122BMC Public Health 2008, 8:22 http://www.biomedcentral.com/1471-2458/8/22
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The calculation of the estimated tobacco-attributable
mortality has two well-defined procedures: one to esti-
mate attributed lung cancer mortality, and the other to
estimate mortality attributable to all the remaining dis-
eases with an established causal relationship [55,56].
The sex- and age-specific proportions of lung cancer
deaths attributable to tobacco are obtained through the
following formula:
(CLC - N*LC)/CLC
For the remainder of the diseases causally associated with
tobacco use, the calculation process is different. The first
step is to estimate thesummarized smoking prevalence or
smoking impact ratio (SIR), which summarizes the his-
tory of tobacco use in the population by age and sex. SIR
was defined as population lung-cancer mortality in excess
of never-smokers, relative to excess lung-cancer mortality
for a known reference group of smokers, adjusted for dif-
ferences in never-smoker lung-cancer mortality rates
across populations [80]. Smokers in the study population
are converted into equivalent of smokers in the reference
population. The formula used for its calculation is:
This formula is used in all populations where lung cancer
mortality rates among non-smokers are unknown. Where
these data are available one needs to normalize the for-
mula [80].
The second step of this process consists of computing the
population etiological fraction (PEF) on the basis of the
previously calculated summarized prevalence (SIR) and
the relative risks of dying due to the respective causes
(RR), by age group and sex, as per the CPS II.
PEF = SIR(RR - 1)/(1 + (SIR(RR - 1)).
To ensure that the resulting PEF was not exaggerated by
excessively high RRs, Peto et al. adjusted the formula pro-
posed by Levin [54] by replacing the 1 in the denominator
by a 2.
Once the RRs from the CPS II had been re-analyzed and
their robustness confirmed, the earlier reduction was
viewed as excessive, and a reduction of 30% applied
instead [81]. In countries like China, where country-spe-
cific risks are available, the reduction applied is lower.
The last step in this procedure would involve applying the
following formula: AM = OM*PEF, in order to obtain the
estimation of attributed mortality, AM, in accordance
with the PEF previously calculated and the observed mor-
tality, OM.
This method has only been applied to estimation of
tobacco-attributable mortality [11,78,79,81-83].
c) Excess mortality methods
Garfinkel's method
Cancer deaths due to smoking are calculated as the differ-
ence between observed and expected deaths in a popula-
tion. To apply this method, age- and sex-specific cancer
mortality rates are needed, and age- and sex-specific can-
cer mortality rates for non-smokers are computed on the
basis of the CPS study [84]. The expected deaths are
related to the number of deaths that would occur if the
whole population was formed by non smokers. To calcu-
late the expected number of deaths, the follow-up over 12
years of the never smokers enrolled at the CPS I study was
employed and death rates for cancer were computed.
These rates were applied to the estimated number of per-
son-years of exposure for non-smokers to obtain the
expected number of deaths for each cancer. The attributa-
ble fractions calculated in this way were similar to those
yielded by the CPS [85]. Garfinkel's method was applied
to estimate cancer mortality attributable to tobacco use
[85-87].
Rogers' method
The method proposed by Rogers et al. [88] combines
prevalence and mortality risk rates in order to offer more
precise estimates of smoking attributable mortality. This
calculation procedure attempts to avoid some problems
related to previous methods as 1) the use of risks derived
from selected populations, 2) the absence of adjustment
for confounding factors or 3) the classification of the
smoking status in crude categories without attending to
the number of cigarettes smoked by former and current
smokers. At first, age-specific smoking prevalence and
mortality risks were estimated. The authors define 7 pop-
ulation groups distinguished by reference to the amount
of cigarettes smoked (p) and classifies them by sex and
age-group: non-smokers, light smokers, moderate and
heavy smokers, light ex-smokers, and moderate and heavy
ex-smokers. To determine the risk of death due to cigarette
smoking, Roger et al. matched data of a health survey to
mortality data. Discrete time hazard models were
employed to compute the risks.
The next step is to determine how many people exist in
each smoking status (n):
n = p*Pop, being Pop the age-specific population in the
area studied.
SIR
CLC NLC
SLC NLC
=
−
− **BMC Public Health 2008, 8:22 http://www.biomedcentral.com/1471-2458/8/22
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The last step is to estimate the excess risk of death (R) of
each smoking status relative to never smokers:
mx,c - mx,n, where mx,c is the age-specific central death rate
for each smoking status and mx,n is the age-specific central
death rate relative to never smokers.
Finally the excess number of deaths is calculated as fol-
lows:
ED = ∑n*(mx,c - mx,n), in the different ages-groups consid-
ered.
This method has been used once to estimate tobacco
attributable mortality [88].
d) Predictive models
These models are represented essentially by one model:
the Prevent model [83].
The Prevent simulation model [83] was developed in
1988 in The Netherlands and is regarded as being a mul-
tifactorial generalization of the etiologic fraction. It has
been used basically to predict mortality due to various
causes, including tobacco [89]. The methodology used
allows, among other factors, for a temporal dimension to
be considered and takes into account the possibility of a
risk factor to associate with more than one disease and a
disease to associate with more than one risk factor. The
process of calculation is tedious and needs knowledge of
multiple data, such as birth- and mortality-rate series or
the likelihood of dying at different ages for each sex [90].
The calculation procedure was described in detail in a
phD dissertation [90] and is summarized elsewhere
[83,91]. Due its scarce use, the calculation procedure is
not described in this paper. However it is important to
introduce two epidemiological effect measures that this
method uses: the "potential impact fraction" and the
"trend impact fraction". Both are indicators of the reduc-
tion in the incidence of a disease in the population stud-
ied, the former reflects changes in the evolution of a
disease after an intervention and the latter is referred to
autonomous or natural trends.
Discussion
This paper constitutes, to our knowledge the first method-
ological review of procedures for estimating smoking-
attributable mortality. In the context of decision-making
it is essential to know, albeit approximately, the impact
that a given risk factor has on the mortality of a popula-
tion. Estimation of tobacco-related mortality is not con-
fined to one procedure alone, inasmuch as any of the
different methods outlined above can be used for the pur-
pose.
Despite the fact that different methodologies have been
found, the foundations of more of them are the same and
only few differences arise in the calculation procedures
(Table 2). Data availability has been taken into account
when choosing a method and also methodology limita-
tions and assumptions have to be considered. Some of
them are described below.
The first limitation affecting intercomparison of methods
and studies stems from the absence of a universal defini-
tion of the categorization of tobacco use. The publications
analyzed furnish different definitions of "smoker", "non-
Table 2: Methodologies' modifications taking into account prevalence-based analysis in cohort studies as base method
Peto's et al method Prevalence-based analysis in 
case-control studies
Basic method
Variation respect 
prevalence-based analysis in 
cohort studies
Problem: Smoking prevalence is a 
poor proxy for cumulative hazards 
of smoking.
Solution: Defining SIR (Smoking 
impact ratio or Synthetic 
prevalence) authors avoid 
prevalence limitations.
Problem: RR extrapolation to 
different populations than the 
original is inconsistent.
Solution: Designing a case-control 
study OR could be assessed.
Problem: RR extrapolation to 
different populations than the 
original is inconsistent.
Solution: RR can be estimated 
applying a calculation procedure.
Calculation procedure
where CLC, NLC, S*LC, N*LC are 
age-sex specific lung cancer 
mortality rates for smokers and 
never smokers in the study and in 
the reference population (*).
where
p1 is the prevalence between the 
cases
a1 is exposed cases
b1 is exposed controls
a0 is non exposed cases
b0 is non exposed controls
Packs-function in smokers
RRs = 1 + ac((t - 5))-t0)
Multistage-function in smokers
RRs = 1 + [(t - 5)4.5 + ac(1 + 2ac)((t 
- 5)-t0)4.5 + 2ac((t - 5)4.5-t0
4.5)]/(t - 
5)4.5
Where a is a constant, c is the 
number of packs of cigarettes 
smoked per year, t is the current 
age and t0 is age at start of smoking.
In former smokers t1 replaces (t - 5) 
and t1 is age at stop smoking.
SIR
CLC NLC
SLC NLC
=
−
− ** OR RR
ab
ab
ap
ap ==
− 10
01
1 1 1
01
()BMC Public Health 2008, 8:22 http://www.biomedcentral.com/1471-2458/8/22
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smoker" and "ex-smoker" [6,92-95], something that inev-
itably determines the result of the estimation [96].
To view smokers as a single entity could lead to a distorted
mortality estimate, since failure to take account of the
number of cigarettes smoked, age at initiation, years of
smoking and other variables that could modify risks val-
ues can occur. It would thus be interesting to explore
tobacco use in the studied populations [88]. A correct clas-
sification of ex-smokers is very important for estimating
and predicting mortality attributable to tobacco use. To
avoid overestimation of attributed mortality, Anthonisen
[97] proposed that account must be taken of the decrease
in risk that takes place at 15 years after quitting the habit.
But this decrease is also determined by the subject's age at
cessation [98,99], the duration of smoking [100] and the
cause studied. The fact that this information was not
expressly gathered in the majority of surveys means that
mortality among ex-smokers may be overestimated. This
problem is solved, at least in part, by ex-smokers reclassi-
fying themselves as non-smokers after the elapse of a long
time without smoking [101].
The second limitation, present mainly in the proportional
method, resides in their reliance on current smoking prev-
alences to reflect mortality occasioned by tobacco use in
previous years. Knowing current smoking prevalence
could be a great help when it comes to predicting future
mortality, but not present[102]: indeed, knowing the
prevalence of tobacco use in any given year could help
predict lung cancer mortality in 20 years' time [103]. As
yet, this problem has no easy solution, due to the absence
of historical series of smoking prevalence in most coun-
tries. Moreover, even if such series were to exist, lack of
knowledge of the latency and induction times for each of
the tobacco-related causes of death would constitute
another problem. The use of current prevalence may over-
estimate or underestimate the attributable mortality. In
countries where the prevalence is decreasing, as U.S.A. or
some European nations, the use of current prevalence is
conservative in the proportional attribution method. The
opposite occurs in countries where prevalence is increas-
ing. Given the unavailability or inaccuracy of prevalence
data, and emphasizing that current prevalence is a poor
proxy for cumulative hazards of smoking, the knowledge
of the period of time from tobacco consumption until
mortality related to this use it is necessary.
Ascertaining the induction period might be feasible if
only one specific component cause was active in triggering
the disease. However, if one allows for the presence of
more than one component cause, then each may have its
own induction time; furthermore, the action of effect
modifiers could alter the induction period [104]. It would
therefore seem that ascertainment of the induction period
is complicated; nevertheless, ascertaining the latency
period is no easy matter either, since it varies according to
the diagnostic methods. What should be clear, however, is
that an induction time is needed for tobacco to cause
harm, and it is for this reason that the age ranges between
30–35 years are considered the time to begin measuring
the effects of exposure. Measuring such effects without
taking into account an induction time could lead to over-
estimated mortality results. On the other hand, some
authors [88] feel that ignoring mortality under the age of
35 years may give rise to underestimates of mortality fig-
ures, due to the existence of individuals who started smok-
ing at early ages.
Peto et al. avoided the problem entailed in prevalence-
dependent methods of attribution. For the application of
their estimation procedure, lack of knowledge of the
tobacco consumption or latency and induction periods
are no a limitation. But this method has not been exempt
from criticism [25,105-110] directed, mainly, at the calcu-
lation of summarized prevalence. Some of these critics
were supported by the tobacco industry, which tried to
undermine the studies focused on estimations of mortal-
ity attributable to tobacco consumption. Peto and col-
leagues defined synthetic prevalence as an indicator that
summarizes a population's smoking history, and calculate
it by assuming CPS II data on lung cancer mortality rates
among smokers and non-smokers to be valid. The use of
these 2 sets of data gave rise to numerous criticisms that
highlighted the low population representativeness of the
CPS II [25,107,111,112]. Most of the population included
in this cohort study was middle class, which may result in
lung cancer mortality in non-smokers being underesti-
mated [88] leading, in turn, to an overestimation of lung
cancer mortality attributable to tobacco use and, by exten-
sion, to an overestimation of the summarized prevalence
[25]. To justify their validity and universality, these data
were compared with those yielded by the study that tar-
geted British physicians [93]; despite the fact that the
results obtained were similar, no conclusion could be
drawn, since the representativeness of this latter study was
also limited. The only thing that could be said was that the
lung cancer mortality rate among non-smokers had not
varied over the years[111]. Nonetheless, in countries
where the use of coal is widespread, lung cancer mortality
among non-smokers is higher, and thus the data, rather
than being drawn from the CPS II, have been drawn from
a local study [72].
The third limitation centers on the absence of world-wide
risk indicators that would reflect the degree of association
between tobacco and smoking related-causes of mortality.
The most widely used effect measure is RR, and a sensitiv-
ity analysis has shown that changes in its value lead to a
greater impact on the estimation of mortality than doBMC Public Health 2008, 8:22 http://www.biomedcentral.com/1471-2458/8/22
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changes in prevalence [102]. Although drawn from differ-
ent sources, the RRs used in the various studies mainly
came from the CPS II [55,56]. Applying these risks to pop-
ulations other than that of the USA aroused criticism
because, inter alia, of their only being adjusted for age and
sex, and because of the difficulty inherent in assimilating
identical tobacco consumption and genetic variability
patterns, or the same influence of confounding factors or
effect modifiers. A solution to these problems was sought
through a re-analysis of the data [9,113-115], and the RRs
were shown robust. Notwithstanding this, the criticisms
continued unabated [116].
The risks obtained from the CPS II are plausible in the
light of current knowledge [25] and have been extrapo-
lated [117] to different EU countries, in absence of other
high quality indicators. Nevertheless, other authors have
chosen to apply RRs which are drawn from studies with
less robust designs or possibly inconsistent with present
knowledge.
A fourth limitation of the attribution methodology is the
uncertainty present in the relationship between exposure,
tobacco use, and different causes of death. While lung
cancer was the first disease to be causally associated with
tobacco use, many studies have observed more causal
associations. The latest report of the Surgeon General [56]
has added 2 further causes of mortality that had not been
considered to date, i.e., stomach cancer and acute myeloid
leukemia and excludes hypertension.
Some methods have been compared by applying them in
the same population. Published comparisons are the indi-
vidual analysis and SAMMEC [3,4], Peto and Prevent
methods [83], Peto and proportional attribution method
[11], and Garfinkel's and proportional attribution
method [85]. The results obtained in all of these compar-
isons have proved to be similar estimations, thereby con-
ferring validity on the respective methodologies.
Observational epidemiology and, despite their limita-
tions, the use of the above-described calculation proce-
dures offer a good approximation of the impact of
tobacco on the mortality of a population [4].
Conclusion
Prior to conducting a study on estimation of tobacco-
attributable mortality, it is essential to assess which
method is best suited to the type and quality of the avail-
able information.
When the mortality estimation objective is going to be the
knowledge of tobacco impact on a population, it is impor-
tant to take into account all the diseases related with con-
sumption. For this reason, the applications of
methodologies that involve all the causes of disease are
important. These methodologies are: Prevalence-based
analysis in cohorts and in case-control studies, Peto et al.
and Roger's methodology. All of them supply accurate
and reliable estimations of mortality attributed to tobacco
consumption.
The absence of a simulation study involving and compar-
ing all calculations procedures do not allow us to recom-
mend a method over other one.
These types of methods furnish estimates that constitute
valuable information and help forming a more accurate
picture of the problem that smoking poses to world
health.
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